Camurus AB (publ) (LON: 0RD1)
London
· Delayed Price · Currency is GBP · Price in SEK
596.00
-3.50 (-0.58%)
Jan 31, 2025, 4:24 PM BST
Camurus AB Revenue
Camurus AB had revenue of 479.60M SEK in the quarter ending September 30, 2024, with 24.90% growth. This brings the company's revenue in the last twelve months to 1.69B, up 4.89% year-over-year. In the year 2023, Camurus AB had annual revenue of 1.72B with 79.52% growth.
Revenue (ttm)
1.69B SEK
Revenue Growth
+4.89%
P/S Ratio
n/a
Revenue / Employee
7.93M SEK
Employees
213
Market Cap
2.55B GBP
Revenue Chart
* This company reports financials in SEK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.72B | 760.51M | 79.52% |
Dec 31, 2022 | 956.34M | 355.77M | 59.24% |
Dec 31, 2021 | 600.57M | 264.57M | 78.74% |
Dec 31, 2020 | 336.00M | 230.39M | 218.16% |
Dec 31, 2019 | 105.61M | 56.28M | 114.12% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Camurus AB News
- 3 months ago - US FDA declines to approve Camurus' rare hormone disorder drug - Reuters
- 7 months ago - New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl - PRNewsWire